Arrow Financial Corp Sells 388 Shares of Celgene Co. (CELG)

Arrow Financial Corp reduced its position in Celgene Co. (NASDAQ:CELG) by 1.6% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 23,309 shares of the biopharmaceutical company’s stock after selling 388 shares during the quarter. Arrow Financial Corp’s holdings in Celgene were worth $3,399,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Assenagon Asset Management S.A. acquired a new position in Celgene in the 3rd quarter valued at $14,700,000. Ingalls & Snyder LLC increased its stake in Celgene by 1.8% in the 3rd quarter. Ingalls & Snyder LLC now owns 27,001 shares of the biopharmaceutical company’s stock valued at $3,937,000 after buying an additional 486 shares during the period. Howe & Rusling Inc. increased its stake in Celgene by 15.6% in the 3rd quarter. Howe & Rusling Inc. now owns 34,859 shares of the biopharmaceutical company’s stock valued at $5,083,000 after buying an additional 4,713 shares during the period. Lincoln Capital Corp grew its stake in shares of Celgene by 4.2% during the 3rd quarter. Lincoln Capital Corp now owns 31,876 shares of the biopharmaceutical company’s stock worth $4,648,000 after purchasing an additional 1,296 shares during the period. Finally, Mutual of America Capital Management LLC grew its stake in shares of Celgene by 6.7% during the 3rd quarter. Mutual of America Capital Management LLC now owns 129,248 shares of the biopharmaceutical company’s stock worth $18,847,000 after purchasing an additional 8,141 shares during the period. 80.16% of the stock is currently owned by institutional investors.

A number of research firms have recently weighed in on CELG. Vetr cut shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $121.72 price target on the stock. in a research note on Monday. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Celgene in a research note on Sunday, December 10th. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a research note on Tuesday, December 12th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $162.00 price target on shares of Celgene in a research note on Tuesday, September 26th. Finally, Leerink Swann reaffirmed a “buy” rating and set a $120.00 price target on shares of Celgene in a research note on Wednesday, December 13th. One research analyst has rated the stock with a sell rating, twelve have issued a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $136.21.

Shares of Celgene Co. (CELG) opened at $109.41 on Monday. Celgene Co. has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The company has a market cap of $86,140.36, a PE ratio of 17.10, a P/E/G ratio of 0.84 and a beta of 1.78.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period in the previous year, the firm earned $1.58 EPS. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. analysts anticipate that Celgene Co. will post 6.68 earnings per share for the current fiscal year.

In other Celgene news, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.95% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Arrow Financial Corp Sells 388 Shares of Celgene Co. (CELG)” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://sportsperspectives.com/2017/12/18/arrow-financial-corp-sells-388-shares-of-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply